Fig. 1From: Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case reportPathological examination of the reported case. A Hematoxylin and eosin (200 ×). B CK7( +) (200 ×). C CK19 (partly +) (200 ×). D HER2 (3 +) (200 ×)Back to article page